108 related articles for article (PubMed ID: 28936999)
21. Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors.
Pietarinen PO; Eide CA; Ayuda-Durán P; Potdar S; Kuusanmäki H; Andersson EI; Mpindi JP; Pemovska T; Kontro M; Heckman CA; Kallioniemi O; Wennerberg K; Hjorth-Hansen H; Druker BJ; Enserink JM; Tyner JW; Mustjoki S; Porkka K
Oncotarget; 2017 Apr; 8(14):22606-22615. PubMed ID: 28186983
[TBL] [Abstract][Full Text] [Related]
22. Reconsideration of BCR-ABL protein flow cytometric immunobead assay: how potent to diagnose and monitor chronic myeloid leukemia?
Kelani R; Monem F
Int J Lab Hematol; 2015 Oct; 37(5):723-8. PubMed ID: 26059167
[TBL] [Abstract][Full Text] [Related]
23. BCR-ABL1 tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.
Cuellar S; Vozniak M; Rhodes J; Forcello N; Olszta D
J Oncol Pharm Pract; 2018 Sep; 24(6):433-452. PubMed ID: 28580869
[TBL] [Abstract][Full Text] [Related]
24. [State-of-the-art management of CML in 2015 and future prospects].
Kimura S
Rinsho Ketsueki; 2015 Oct; 56(10):2005-14. PubMed ID: 26458439
[TBL] [Abstract][Full Text] [Related]
25. Multifaceted mechanisms for cell survival and drug targeting in chronic myelogenous leukemia.
Kuroda J; Shimura Y; Yamamoto-Sugitani M; Sasaki N; Taniwaki M
Curr Cancer Drug Targets; 2013 Jan; 13(1):69-79. PubMed ID: 22414011
[TBL] [Abstract][Full Text] [Related]
26. Patients' and hematologists' concerns regarding tyrosine kinase-inhibitor therapy in chronic myeloid leukemia.
Jiang Q; Yu L; Gale RP
J Cancer Res Clin Oncol; 2018 Apr; 144(4):735-741. PubMed ID: 29380058
[TBL] [Abstract][Full Text] [Related]
27. Characterization of imatinib-resistant K562 cell line displaying resistance mechanisms.
Hekmatshoar Y; Ozkan T; Altinok Gunes B; Bozkurt S; Karadag A; Karabay AZ; Sunguroglu A
Cell Mol Biol (Noisy-le-grand); 2018 May; 64(6):23-30. PubMed ID: 29808796
[TBL] [Abstract][Full Text] [Related]
28. Additional chromosome abnormalities, BCR-ABL tyrosine kinase domain mutations and clinical outcome in Hungarian tyrosine kinase inhibitor-resistant chronic myelogenous leukemia patients.
Meggyesi N; Kozma A; Halm G; Nahajevszky S; Bátai A; Fekete S; Barta A; Ujj G; Lueff S; Sipos A; Adám E; Bors A; Reményi P; Masszi T; Tordai A; Andrikovics H
Acta Haematol; 2012; 127(1):34-42. PubMed ID: 22005133
[TBL] [Abstract][Full Text] [Related]
29. Minimal Residual Disease Eradication in CML: Does It Really Matter?
Tantravahi SK; Guthula RS; O'Hare T; Deininger MW
Curr Hematol Malig Rep; 2017 Oct; 12(5):495-505. PubMed ID: 28852963
[TBL] [Abstract][Full Text] [Related]
30. Bosutinib: a review of its use in patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
Syed YY; McCormack PL; Plosker GL
BioDrugs; 2014 Feb; 28(1):107-20. PubMed ID: 24420842
[TBL] [Abstract][Full Text] [Related]
31. Generic imatinib in the treatment of chronic myeloid leukemia: two years' experience in Latvia.
Lejniece S; Udre I; Rivkina A
Exp Oncol; 2017 Jul; 39(2):151-154. PubMed ID: 29483494
[TBL] [Abstract][Full Text] [Related]
32. Discontinuation of tyrosine kinase therapy in CML.
Mahon FX
Ann Hematol; 2015 Apr; 94 Suppl 2():S187-93. PubMed ID: 25814085
[TBL] [Abstract][Full Text] [Related]
33. Discontinuing Tyrosine Kinase Inhibitor Therapy in Chronic Myelogenous Leukemia: Current Understanding and Future Directions.
Bhalla S; Tremblay D; Mascarenhas J
Clin Lymphoma Myeloma Leuk; 2016 Sep; 16(9):488-494. PubMed ID: 27406834
[TBL] [Abstract][Full Text] [Related]
34. Bosutinib : a review of preclinical and clinical studies in chronic myelogenous leukemia.
Rusconi F; Piazza R; Vagge E; Gambacorti-Passerini C
Expert Opin Pharmacother; 2014 Apr; 15(5):701-10. PubMed ID: 24479382
[TBL] [Abstract][Full Text] [Related]
35. [Molecular biology and treatment of CML].
Kimura S
Rinsho Ketsueki; 2017; 58(10):1920-1930. PubMed ID: 28978834
[TBL] [Abstract][Full Text] [Related]
36. Monitoring minimal residual disease and controlling drug resistance in chronic myeloid leukaemia patients in treatment with imatinib as a guide to clinical management.
Martinelli G; Iacobucci I; Soverini S; Cilloni D; Saglio G; Pane F; Baccarani M
Hematol Oncol; 2006 Dec; 24(4):196-204. PubMed ID: 16988930
[TBL] [Abstract][Full Text] [Related]
37. Evolving treatment strategies for patients newly diagnosed with chronic myeloid leukemia: the role of second-generation BCR-ABL inhibitors as first-line therapy.
Shami PJ; Deininger M
Leukemia; 2012 Feb; 26(2):214-24. PubMed ID: 21844872
[TBL] [Abstract][Full Text] [Related]
38. Tyrosine Kinase Inhibitors in Ph+ Chronic Myeloid Leukemia Therapy: a Review.
Shah K; Parikh S; Rawal R
Asian Pac J Cancer Prev; 2016; 17(7):3025-33. PubMed ID: 27509925
[TBL] [Abstract][Full Text] [Related]
39. Hematological and molecular response evaluation of CML patients on imatinib.
Gupta A; Prasad K
J Assoc Physicians India; 2007 Feb; 55():109-13. PubMed ID: 17571739
[TBL] [Abstract][Full Text] [Related]
40. Management of adverse events associated with tyrosine kinase inhibitors in chronic myeloid leukemia.
Rea D
Ann Hematol; 2015 Apr; 94 Suppl 2():S149-58. PubMed ID: 25814081
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
